Eli Lilly, Nimbus Tie Up in USD 1.35 Billion AI-Driven Pact to Develop Oral Obesity Drugs
Nimbus will use its AI to help identify drug candidates, while Lilly will contribute its metabolic-disease expertise to develop an easy-to-take oral medicine for obesity.
Written By : sheeba farhat
Published On 2026-01-07 10:41 GMT | Update On 2026-01-07 10:41 GMT
Advertisement
Bengaluru: Nimbus Therapeutics said on Tuesday it has entered into a multi-year research and licensing agreement with Eli Lilly to develop artificial intelligence-driven new oral treatments for obesity and other metabolic diseases.
The U.S. drugmaker will make upfront and near-term milestone payments of $55 million, with an additional $1.3 billion in development and commercial milestones to Nimbus, as well as royalties on global sales if the drug is approved.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.